Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could VR help sharpen your mind? new study tests brain training in virtual reality

NCT ID NCT06038955

Symptom relief Sponsor: Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether a 4-week virtual reality (VR) training program could improve thinking skills in 62 people with depression, bipolar disorder, or psychotic disorders like schizophrenia. Participants practiced daily-life tasks in VR, such as cooking and shopping, guided by a therapist. The goal was to see if this training helps with memory, attention, and planning better than a control VR activity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
virtual reality-based cognitive remediation training
What this could lead to
If it works, this could offer a new, engaging way to improve daily thinking skills like memory and planning for people with mood or psychotic disorders.
What could go wrong
This is a small, early-stage trial with only 62 participants. The training is short (4 weeks), and benefits may not last or apply to everyone. The primary outcome is a VR test, which may not reflect real-world improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

62 people

The number who actually took part.

Started

Oct 2022

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Fluent Danish skills * Meet the International Classification of Diseases 10th edition (ICD-10) diagnosis of unipolar disorder, bipolar disorder (types I and II) or a psychosis spectrum disorder (i.e. F20-F29) confirmed using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview * Patients must have objective and subjective cognitive impairment at the time of inclusion. Objective cognitive impairment is defined a total score on the Screen for Cognitive Impairment in Psychiatry - Danish version (SCIP-D) ≥ 0.5 standard deviations (SD) below the expected total score based on age, education, and gender or as a score ≥ 0.5 SD below the expected score on a minimum of two out of the five subtests (verbal learning test - immediate, working memory test, verbal fluency test, verbal learning, test - delayed, and processing speed test). Subjective cognitive impairment is defined as a score ≥ 14 on the Cognitive Complaints in Bipolar Disorder Rating Scale (COBRA). Exclusion Criteria: * Current drug or substance abuse * A daily use of benzodiazepines \>22.5 mg oxazepam or \>7.5 mg diazepam (cutoffs for doses with limited cognitive side effects) * Comorbid neurological disorder * Previous serious head trauma * Dyslexia * Pregnancy * Claustrophobia (fMRI scan) * Having a pacemaker or other metal implants inside the body (fMRI scan) * Having had electroconvulsive therapy in the 3 months prior to inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bipolar disorder Cognitive Dysfunction Depression depressive disorder major depressive disorder psychotic disorder Psychotic Disorders schizophrenia schizotypal personality disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bipolar disorder Cognitive impairment Depression Psychotic disorders Schizophrenia Schizotypal disorder

Contacts and locations

Locations

  • Neurocognition and Emotion in Affective Disorders (NEAD) Centre, Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Frederiksberg hospital

    Frederiksberg, Capital Region of Copenhagen, 2000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.